MeSH term
Frequency | Condition_Probility | Aged | 19 | 0.0 |
Humans | 150 | 0.0 |
Risk | 2 | 0.0 |
Time Factors | 6 | 0.0 |
Animals | 42 | 0.0 |
CHO Cells | 6 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Hamsters | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 101 | 0.0 |
Transfection | 4 | 0.0 |
Disease Progression | 4 | 0.0 |
Genetic Predisposition to Disease | 14 | 0.0 |
Adolescent | 21 | 0.0 |
Antigens, Differentiation/*genetics | 60 | 42.0 |
Case-Control Studies | 21 | 0.0 |
Child | 16 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 11 | 5.0 |
Female | 54 | 0.0 |
Gene Frequency | 23 | 0.0 |
Genotype | 29 | 0.0 |
Male | 48 | 0.0 |
Phenotype | 8 | 0.0 |
*Polymorphism, Single Nucleotide | 7 | 1.0 |
Adult | 36 | 0.0 |
Haplotypes | 7 | 0.0 |
Polymorphism, Single Nucleotide | 6 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 31 | 0.0 |
Exons | 12 | 0.0 |
*Immunoconjugates | 79 | 22.0 |
*Lymphocyte Activation | 10 | 0.0 |
Middle Aged | 25 | 0.0 |
*Polymorphism, Genetic | 33 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
T-Lymphocytes/*immunology | 17 | 0.0 |
DNA/analysis | 3 | 0.0 |
Graves' Disease/*genetics | 5 | 13.0 |
Linkage Disequilibrium | 9 | 1.0 |
Polymerase Chain Reaction | 19 | 0.0 |
Polymorphism, Restriction Fragment Length | 9 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Signal Transduction | 4 | 0.0 |
Alleles | 24 | 0.0 |
Dinucleotide Repeats | 2 | 2.0 |
Minisatellite Repeats | 3 | 2.0 |
Spain | 3 | 0.0 |
Antigens, CD28/genetics | 7 | 36.0 |
Antigens, Differentiation/genetics | 11 | 35.0 |
Antigens, Differentiation, T-Lymphocyte/*genetics | 5 | 9.0 |
Base Sequence | 14 | 0.0 |
Chromosomes, Human, Pair 2/genetics | 3 | 2.0 |
Finland | 4 | 1.0 |
Introns | 2 | 0.0 |
Linkage (Genetics) | 13 | 0.0 |
T-Lymphocytes/immunology | 9 | 0.0 |
Child, Preschool | 11 | 0.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 4 | 7.0 |
*Genetic Predisposition to Disease | 14 | 1.0 |
HLA Antigens/genetics | 4 | 1.0 |
HLA-DQ Antigens/genetics | 8 | 3.0 |
HLA-DR Antigens/genetics | 5 | 1.0 |
Infant | 7 | 0.0 |
Japan | 5 | 0.0 |
CD8-Positive T-Lymphocytes/immunology | 3 | 0.0 |
*Immune Tolerance | 2 | 1.0 |
Mice | 28 | 0.0 |
Mice, Inbred NOD | 3 | 1.0 |
Antibodies, Monoclonal | 5 | 0.0 |
Cell Line | 5 | 0.0 |
Immune Tolerance/*immunology | 2 | 4.0 |
Immunophenotyping | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
Gene Expression | 5 | 0.0 |
Interferon Type II/genetics | 3 | 3.0 |
Lymphocyte Activation | 15 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Celiac Disease/*genetics | 5 | 17.0 |
Genetic Predisposition to Disease/genetics | 4 | 0.0 |
Linkage Disequilibrium/genetics | 2 | 1.0 |
Sweden | 2 | 0.0 |
Antigens, CD80/*chemistry/*metabolism | 2 | 66.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Kinetics | 2 | 0.0 |
Ligands | 6 | 0.0 |
Protein Binding | 2 | 0.0 |
Antigens, CD28/*genetics | 4 | 19.0 |
*Chromosomes, Human, Pair 2 | 4 | 1.0 |
Microsatellite Repeats/genetics | 4 | 1.0 |
Molecular Sequence Data | 18 | 0.0 |
*Multigene Family | 2 | 0.0 |
Polymorphism, Genetic | 9 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Species Specificity | 4 | 0.0 |
Autoimmune Diseases/*genetics | 5 | 11.0 |
*Chromosome Mapping | 6 | 0.0 |
Immunosuppressive Agents | 2 | 16.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Flow Cytometry | 8 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Graves' Disease/etiology/*genetics | 2 | 66.0 |
Logistic Models | 2 | 0.0 |
Ethnic Groups/genetics | 3 | 1.0 |
Receptors, Tumor Necrosis Factor/genetics | 2 | 4.0 |
Autoimmune Diseases/*genetics/*immunology | 2 | 40.0 |
Celiac Disease/genetics/immunology | 2 | 100.0 |
Microsatellite Repeats | 6 | 0.0 |
Risk Factors | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 3 | 0.0 |
Chromosome Mapping | 7 | 0.0 |
Epitopes/immunology | 2 | 0.0 |
Immunoglobulins, Fc/genetics | 3 | 18.0 |
Diabetes Mellitus, Type 1/ethnology/*genetics | 3 | 27.0 |
Immunoglobulin E/*blood | 2 | 3.0 |
Antigens, Differentiation/biosynthesis/*genetics | 2 | 22.0 |
Multiple Sclerosis/*genetics | 6 | 7.0 |
Antigens, Differentiation/immunology | 3 | 2.0 |
Dendritic Cells/*immunology | 3 | 1.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Antigens, Differentiation/*physiology | 2 | 2.0 |
Cell Division | 2 | 0.0 |
Interleukin-2/biosynthesis | 6 | 1.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Age of Onset | 3 | 0.0 |
Comparative Study | 16 | 0.0 |
Exons/genetics | 3 | 0.0 |
Heterozygote | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 3 | 1.0 |
Russia | 3 | 3.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Cell Division/immunology | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Mutation | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Signal Transduction/immunology | 5 | 1.0 |
T-Lymphocytes/cytology/*immunology | 2 | 1.0 |
Asian Continental Ancestry Group/*genetics | 5 | 1.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Haplotypes/genetics | 3 | 0.0 |
Antigens, CD/genetics | 2 | 1.0 |
Diabetes Mellitus, Type 1/genetics/immunology | 2 | 16.0 |
Disease Models, Animal | 2 | 0.0 |
Rats | 4 | 0.0 |
Antigens, CD/*biosynthesis/genetics | 2 | 3.0 |
Antigens, CD28/*metabolism | 5 | 4.0 |
Antigens, Differentiation/*metabolism | 7 | 5.0 |
Cell Line, Transformed | 2 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Protein Binding/immunology | 3 | 1.0 |
Amino Acid Substitution | 5 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Germany | 3 | 0.0 |
Reference Values | 3 | 0.0 |
Diabetes Mellitus, Type 1/genetics | 2 | 5.0 |
Lymphocyte Depletion | 2 | 1.0 |
Amino Acid Sequence | 10 | 0.0 |
Antigens, CD/metabolism | 4 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Immunosuppressive Agents/*pharmacology | 2 | 0.0 |
Membrane Glycoproteins/metabolism | 4 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
English Abstract | 6 | 0.0 |
Genetic Markers | 7 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Chromosomes, Human, Pair 2/*genetics | 7 | 4.0 |
Genetic Predisposition to Disease/*genetics | 6 | 1.0 |
Norway | 2 | 1.0 |
Antigens, CD/*analysis | 2 | 0.0 |
Antigens, CD80/*analysis | 2 | 13.0 |
Biopsy | 2 | 0.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
Recombinant Fusion Proteins/genetics | 2 | 1.0 |
Confidence Intervals | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Antigens, CD/analysis | 3 | 0.0 |
Antigens, Differentiation/analysis | 3 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 2 | 0.0 |
Graft Rejection/immunology | 2 | 3.0 |
Up-Regulation | 5 | 0.0 |
HLA-DR3 Antigen/genetics | 2 | 8.0 |
Variation (Genetics) | 3 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/genetics | 2 | 6.0 |
Chromosomes, Human, Pair 2 | 2 | 1.0 |
Gene Expression Regulation | 2 | 0.0 |
Cytokines/biosynthesis | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Antigens, CD40/biosynthesis | 2 | 7.0 |
Biological Markers | 2 | 0.0 |
CD40 Ligand | 4 | 2.0 |
Membrane Glycoproteins/biosynthesis | 2 | 1.0 |
Retrospective Studies | 2 | 0.0 |
Antigens, CD/*metabolism | 4 | 0.0 |
Antigens, CD80/*metabolism | 7 | 12.0 |
Membrane Glycoproteins/*metabolism | 2 | 0.0 |
Arthritis, Rheumatoid/*genetics/immunology | 2 | 4.0 |
Immunoglobulins, Fc/*genetics | 2 | 66.0 |
Gene Library | 2 | 0.0 |
Recombinant Fusion Proteins/immunology | 2 | 1.0 |
Antigens, CD28/immunology | 3 | 2.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Antigens, CD28/*immunology/metabolism | 2 | 28.0 |
Cell Differentiation | 2 | 0.0 |
Clonal Anergy | 3 | 8.0 |
Antigens, CD80/analysis | 2 | 4.0 |
B-Lymphocytes/*immunology | 5 | 0.0 |
Membrane Glycoproteins/analysis | 2 | 0.0 |
Antigens, CD28/metabolism | 5 | 5.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Phosphorylation | 2 | 0.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Immunosuppression | 3 | 1.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
DNA Primers | 4 | 0.0 |
Lupus Erythematosus, Systemic/*genetics | 2 | 3.0 |
Polymorphism, Single Nucleotide/genetics | 3 | 1.0 |
Antigens, CD80/immunology | 3 | 4.0 |
Mice, Inbred C3H | 2 | 0.0 |
Alanine/genetics | 2 | 1.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Threonine/genetics | 2 | 2.0 |
Antigens, CD80/metabolism | 2 | 2.0 |
Antigens, CD/physiology | 2 | 0.0 |
Antigens, CD28/*physiology | 3 | 3.0 |
Antigens, CD80/physiology | 2 | 6.0 |
Antigens, Differentiation/physiology | 3 | 5.0 |
Antigens, CD80/*physiology | 2 | 4.0 |
DNA Primers/chemistry | 2 | 0.0 |
Family | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 2 | 0.0 |
T-Lymphocytes/*immunology/metabolism | 2 | 1.0 |
Antigens, Differentiation/*immunology | 3 | 2.0 |
Autoimmunity/*genetics | 3 | 21.0 |
Antigens, CD28/*immunology | 3 | 2.0 |
Lymphocyte Activation/*immunology | 3 | 0.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Cell Communication | 2 | 0.0 |
T-Lymphocyte Subsets/*immunology | 4 | 0.0 |
Arthritis, Rheumatoid/*genetics | 2 | 2.0 |
DNA/genetics | 2 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
Apoptosis/*immunology | 2 | 1.0 |
Antigens, CD28 | 3 | 2.0 |
Antigens, CD80 | 3 | 9.0 |
In Vitro | 4 | 0.0 |
Antigens, CD28/analysis | 2 | 5.0 |
Odds Ratio | 2 | 0.0 |
Virus Replication | 2 | 0.0 |
Antigens, Differentiation/genetics/*immunology | 3 | 23.0 |
Cytokines/*genetics | 2 | 1.0 |
Follow-Up Studies | 2 | 0.0 |
Lod Score | 2 | 0.0 |
